Genomma Lab Internacional S.A.B. de C.V (LABB) - Net Assets
Based on the latest financial reports, Genomma Lab Internacional S.A.B. de C.V (LABB) has net assets worth MX$11.11 Billion MXN (≈ $639.47 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (MX$23.83 Billion ≈ $1.37 Billion USD) and total liabilities (MX$12.72 Billion ≈ $732.22 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LABB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | MX$11.11 Billion |
| % of Total Assets | 46.62% |
| Annual Growth Rate | 23.43% |
| 5-Year Change | 10.32% |
| 10-Year Change | 63.57% |
| Growth Volatility | 66.49 |
Genomma Lab Internacional S.A.B. de C.V - Net Assets Trend (2005–2025)
This chart illustrates how Genomma Lab Internacional S.A.B. de C.V's net assets have evolved over time, based on quarterly financial data. Also explore LABB total assets for the complete picture of this company's asset base.
Annual Net Assets for Genomma Lab Internacional S.A.B. de C.V (2005–2025)
The table below shows the annual net assets of Genomma Lab Internacional S.A.B. de C.V from 2005 to 2025. For live valuation and market cap data, see how much is Genomma Lab Internacional S.A.B. de C.V worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | MX$11.11 Billion ≈ $639.47 Million |
-4.12% |
| 2024-12-31 | MX$11.59 Billion ≈ $666.93 Million |
+23.51% |
| 2023-12-31 | MX$9.38 Billion ≈ $539.98 Million |
-7.58% |
| 2022-12-31 | MX$10.15 Billion ≈ $584.28 Million |
+0.80% |
| 2021-12-31 | MX$10.07 Billion ≈ $579.66 Million |
+4.55% |
| 2020-12-31 | MX$9.63 Billion ≈ $554.45 Million |
+20.82% |
| 2019-12-31 | MX$7.97 Billion ≈ $458.91 Million |
+7.35% |
| 2018-12-31 | MX$7.43 Billion ≈ $427.47 Million |
+5.38% |
| 2017-12-31 | MX$7.05 Billion ≈ $405.65 Million |
+3.77% |
| 2016-12-31 | MX$6.79 Billion ≈ $390.93 Million |
-26.55% |
| 2015-12-31 | MX$9.25 Billion ≈ $532.26 Million |
-11.94% |
| 2014-12-31 | MX$10.50 Billion ≈ $604.46 Million |
+18.87% |
| 2013-12-31 | MX$8.84 Billion ≈ $508.48 Million |
+25.88% |
| 2012-12-31 | MX$7.02 Billion ≈ $403.94 Million |
+25.95% |
| 2011-12-31 | MX$5.57 Billion ≈ $320.72 Million |
+35.54% |
| 2010-12-31 | MX$4.11 Billion ≈ $236.63 Million |
+34.78% |
| 2009-12-31 | MX$3.05 Billion ≈ $175.57 Million |
+31.94% |
| 2008-12-31 | MX$2.31 Billion ≈ $133.06 Million |
+293.60% |
| 2007-12-31 | MX$587.44 Million ≈ $33.81 Million |
+69.75% |
| 2006-12-31 | MX$346.07 Million ≈ $19.92 Million |
+109.83% |
| 2005-12-31 | MX$164.93 Million ≈ $9.49 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genomma Lab Internacional S.A.B. de C.V's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1221914400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | MX$12.22 Billion | 109.97% |
| Total Equity | MX$11.11 Billion | 100.00% |
Genomma Lab Internacional S.A.B. de C.V Competitors by Market Cap
The table below lists competitors of Genomma Lab Internacional S.A.B. de C.V ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hongsheng Heat Exchanger Mnfg
SHG:603090
|
$939.30 Million |
|
Smartgroup Corporation Ltd
AU:SIQ
|
$939.35 Million |
|
Yuanli Chemical Group Co Ltd
SHG:603217
|
$939.38 Million |
|
Insperity Inc
NYSE:NSP
|
$940.19 Million |
|
Tianjin Economic-technological Development Area Co Ltd
SHE:000652
|
$939.26 Million |
|
Hunan Jiudian Pharmaceutical Co Ltd
SHE:300705
|
$939.12 Million |
|
CW Enerji SA
IS:CWENE
|
$938.99 Million |
|
Shenyang Blue Silver Ind Auto
SHE:300293
|
$938.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genomma Lab Internacional S.A.B. de C.V's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,588,594,000 to 11,111,429,000, a change of -477,165,000 (-4.1%).
- Net income of 1,607,387,000 contributed positively to equity growth.
- Dividend payments of 781,772,000 reduced retained earnings.
- Other factors decreased equity by 1,302,780,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | MX$1.61 Billion | +14.47% |
| Dividends Paid | MX$781.77 Million | -7.04% |
| Other Changes | MX$-1.30 Billion | -11.72% |
| Total Change | MX$- | -4.12% |
Book Value vs Market Value Analysis
This analysis compares Genomma Lab Internacional S.A.B. de C.V's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.37x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.57x to 1.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | MX$6.53 | MX$16.76 | x |
| 2018-12-31 | MX$7.30 | MX$16.76 | x |
| 2019-12-31 | MX$7.83 | MX$16.76 | x |
| 2020-12-31 | MX$9.47 | MX$16.76 | x |
| 2021-12-31 | MX$10.04 | MX$16.76 | x |
| 2022-12-31 | MX$10.53 | MX$16.76 | x |
| 2023-12-31 | MX$9.90 | MX$16.76 | x |
| 2024-12-31 | MX$12.26 | MX$16.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genomma Lab Internacional S.A.B. de C.V utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.47%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.16%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 2.15x
- Recent ROE (14.47%) is above the historical average (13.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 22.31% | 19.62% | 0.93x | 1.23x | MX$284.64 Million |
| 2009 | 25.32% | 17.41% | 1.04x | 1.39x | MX$466.10 Million |
| 2010 | 26.26% | 17.12% | 1.07x | 1.43x | MX$664.11 Million |
| 2011 | 25.25% | 17.30% | 0.88x | 1.66x | MX$843.67 Million |
| 2012 | 22.47% | 15.97% | 0.75x | 1.87x | MX$868.63 Million |
| 2013 | 20.12% | 15.43% | 0.65x | 1.99x | MX$881.34 Million |
| 2014 | 13.91% | 12.40% | 0.45x | 2.47x | MX$402.34 Million |
| 2015 | -11.89% | -9.68% | 0.63x | 1.96x | MX$-1.97 Billion |
| 2016 | -25.54% | -14.85% | 0.72x | 2.39x | MX$-2.34 Billion |
| 2017 | 18.68% | 10.59% | 0.76x | 2.32x | MX$594.53 Million |
| 2018 | 14.94% | 9.41% | 0.65x | 2.43x | MX$366.68 Million |
| 2019 | 9.59% | 6.01% | 0.66x | 2.41x | MX$-32.95 Million |
| 2020 | 15.26% | 10.60% | 0.63x | 2.30x | MX$506.96 Million |
| 2021 | 12.98% | 8.44% | 0.72x | 2.14x | MX$300.64 Million |
| 2022 | 13.68% | 8.26% | 0.78x | 2.13x | MX$373.95 Million |
| 2023 | 10.94% | 6.23% | 0.80x | 2.21x | MX$88.04 Million |
| 2024 | 12.88% | 8.02% | 0.77x | 2.08x | MX$334.26 Million |
| 2025 | 14.47% | 9.16% | 0.74x | 2.15x | MX$496.24 Million |
Industry Comparison
This section compares Genomma Lab Internacional S.A.B. de C.V's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
No peer company data available for comparison.
About Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products t… Read more